Showing 4091-4100 of 4164 results for "".
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar
- SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA for Dry Eye Drophttps://modernod.com/news/silktech-biopharmaceuticals-ind-submission-cleared-by-fda-phase-2-clinical-trial-initiated-for-patients-with-dry-eye-disease/2476469/SilkTech Biopharmaceuticals announced the company has received clearance of its investigational new drug (IND) submission with the FDA for its SDP-4 eye drop product. In addition, the company has initiated a phase 2 clinical trial for its first-in-class drug to assess the safety and efficacy of t
- Aldeyra Therapeutics Announces Positive Results From Phase 3 Allergic Conjunctivitis Trialhttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-the-phase-3-alleviate-trial-in-patients-with-allergic-conjunctivitis/2476416/Aldeyra Therapeutics announced positive results from the phase 3 ALLEVIATE trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary and the key secondary endpoint for both concentrations of reproxalap. “We a
- Alkahest Presents Positive Phase 2a Study Results of AKST4290 for Treatment-Naïve Wet AMDhttps://modernod.com/news/alkahest-presents-positive-phase-2a-study-results-of-akst4290-for-treatment-naive-wet-amd/2476414/Alkahest shared results from its open label study, ALK4290-201. The data were delivered during a podium presentation as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress. The study evaluated the therapeutic effect an
- GenSight Biologics to Present 72-Week Data From the REVERSE Phase 3 Trial of GS010https://modernod.com/news/gensight-biologics-to-present-72-week-data-from-the-reverse-phase-3-trial-of-gs010/2476389/GenSight Biologics announced that the 72-week results from the REVERSE Phase 3 clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), which will be held in Las Vegas from March 16 to 21, 2019. The results will be presented b
- Aerpio Pharmaceuticals Does Not Meet Primary Endpoint in Phase 2b Study for Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-does-not-meet-primary-endpoint-in-phase-2b-study-for-diabetic-retinopathy/2476386/Aerpio Pharmaceuticals announced topline results from the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). Administration o
- Study Demonstrates Long-Term IOP Reduction with the OMNI Surgical System Predicate Device (TRAB 360) in MIGShttps://modernod.com/news/clinical-study-demonstrates-long-term-iop-reduction-with-the-omni-surgical-system-predicate-device-trab-360-in-migs/2476378/A new, single-center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI Surgical System’s Predicate Devices (TRAB 360)
- ProQR Reports First Patient Dosing in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-reports-first-patient-dosing-in-phase-1-2-stellar-trial-of-qr-421a-for-usher-syndrome-type-2/2476365/ProQR Therapeutics announced the first patient dosed in the phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019. “There are no effective treat
- Roche/Genentech Initiate Two Large Phase 3 Studies in Wet AMD for Bispecific Molecule, Faricimabhttps://modernod.com/news/roche-genentech-initiate-two-large-phase-3-studies-in-wet-amd-for-bispecific-molecule-faricimab/2476355/Roche and Genentech have initiated two large global phase 3 clinical trials in wet age-related macular degeneration (AMD) investigating the bispecific molecule, faricimab. Faricimab is the first bispecific antibody designed specifically for the treatment of retinal eye diseases that simultaneousl
- Staar Surgical Announces Strategic Cooperation Agreement with Vista Oftalmólogoshttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-vista-oftalmologos/2479594/Staar Surgical Company announced a strategic cooperation agreement with Vista Oftalmólogos, a 49-clinic ophthalmology group spanning Spain, France, Portugal, and Morocco with more than 200 eye doctors and 1,000 employees. The agreement positions the EVO Visian ICL family of lenses as a premium an